Monitoring Program for Mucopolysaccharidosis VII Sly Syndrome to Study Disease Progression and Long-Term Effects of Vestronidase Alfa

What this Trial Is About

Researchers are studying Mucopolysaccharidosis VII MPS VII, also known as Sly Syndrome, to understand its presentation and progression over time. This observational program aims to collect detailed data on how MPS VII affects patients, including both those who receive vestronidase alfa treatment and those who do not. The study evaluates long-term safety and effectiveness of vestronidase alfa, focusing on allergic reactions and immune responses. Participants may be treated with vestronidase alfa accessed through prescription or compassionate use programs, or they may receive no treatment or other treatments outside the study. This non-randomized, global, multicenter study gathers information prospectively to capture changes in biomarkers, clinical signs, and patient or caregiver-reported outcomes. Data collection follows standardized procedures across multiple sites to ensure quality. During the study, participants attend regular visits to provide clinical assessments, biomarker samples, and complete questionnaires about their health and symptoms. The research team monitors the clinical course of MPS VII, the long-term effects and safety of vestronidase alfa, including hypersensitivity and immunogenicity, over a period of up to 10 years. The study involves both treated and untreated patients, aiming to build a comprehensive dataset on disease progression and treatment impact.

Mucopolysaccharidosis VII Disease Monitoring Program